Trial finds monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive hyperinflammatory condition—who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD…